scientists holding early cancer detection blood tests

early cancer detection
blood tests

Freenome aims to detect cancer earlier and make cancer screening more accessible through standard blood tests.

early cancer detection blood test icon

Using a standard blood draw for early cancer detection

Our goal is to meet patients where they are. We are developing blood tests to be easy to administer and fit within routine healthcare. Our tests are developed using our comprehensive multiomics platform to enable us to detect the body’s earliest warning signs of cancer.

Learn more about our multiomics platform

Our colorectal cancer screening blood test

Our first blood test in development is for colorectal cancer (CRC) — the second deadliest cancer in the United States.1 Together, we can change that statistic. Even though CRC is one of the most fatal cancers today, it is also one of the most treatable when detected early.1

Despite multiple screening options, almost 4 in 10 people who are eligible for CRC screening don't get screened.2 We seek to improve this statistic by developing an accessible blood test that makes it easier to get screened and, therefore, detect CRC in its earliest stages.

Our CRC blood test is currently being validated through PREEMPT CRC®, the largest clinical study validating a blood-based colorectal screening test.

Learn more about Our FDA Clinical study, preempt CRC
colorectal cancer screening options

Our multi-cancer tests:
One size does not fit all

Colorectal cancer is just one of many cancers for which we are developing early detection blood tests.

A lot of people may not realize there are more than 100 cancers — making detection, diagnosis, and treatment not a one-size-fits-all process. That’s why Freenome is developing a tailored approach for our multi-cancer screening tests. This ensures each test is optimized for different cancer signals, screening goals, and diagnostic and care pathways to ultimately improve patient outcomes. The Vallania Study and The Sanderson Study are our multi-cancer clinical studies currently enrolling patients across the United States.

Learn more about our multiomics platform Learn about our multi-cancer clinical studies
early cancer detection blood tests